Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic BM-MSC for Severe Viral-Induced ARDS
NCT02215811Phase 1Unknown
- Sponsor
- Karolinska University Hospital
- Start
- Mar 2014
- Primary completion
- Dec 2015
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Provacel in acute respiratory distress syndrome (ARDS), sponsored by Karolinska University Hospital. Primary endpoint: In-hospital mortality at 2 months. Status: unknown.
02
Drugs
Provacel
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT02215811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215811.